Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT06797297 |
| Consolidated Lead Sponsor | Innovent Biologics (Suzhou) Co |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | ACTIVE NOT RECRUITING |
| Registered Enrollment | 203 participants (ACTUAL) |
| Registered Start Date | 2025-02-24 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Chongqing University Cancer Hospital | Chongqing, China | Open Hospital Dossier -> |
| Fujian Cancer Hospital | Fuzhou, China | Open Hospital Dossier -> |
| Sun Yat-sen University Cancer Center | Guangzhou, China | Open Hospital Dossier -> |
| Harbin Medical University Cancer Hospital | Harbin, China | Open Hospital Dossier -> |
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.